Skip to content | Change text size
 

Dr Lisa M Kaminskas

NHMRC Australian Biomedical Training Fellow

B HealthSci(Hons)  University of Adelaide
PhD University of Adelaide

Phone: +61 3 9903 9741
Fax: +61 3 9903 9583
Email: lisa.kaminskas@pharm.monash.edu.au

Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences

Research interests

  • Dendrimer biopharmaceutics
  • Nanoparticle based cancer therapeutics
  • Lymphatic drug targeting
  • Drug delivery to lymphatic sites of metastasis

Representative publications

  1. Kaminskas LM, Kelly B, McLeod VM, Boyd, BJ, Krippner GY, Williams ED, Porter CJH. Pharmacokinetics and tumour disposition of PEGylated methotrexate conjugated poly-L-lysine dendrimers. Mol Pharm. 2009. Accepted.
  2. Kaminskas LM, Wu Z, Barlow N, Krippner GY, Boyd BJ, Porter CJH. Partly-PEGylated poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers. J Pharm Sci. 2009. Accepted.
  3. Kaminskas LM, Boyd BJ, Karellas P, Krippner GY, Lessene R, Kelly B, Porter CJH. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly-L-lysine dendrimers. Mol Pharm. 2008; 5: 449-463.
  4. Kaminskas LM, Boyd BJ, Karellas P, Henderson SA, Giannis MP, Krippner GY, Porter CJH. Impact of surface derivatisation of poly-L-lysine dendrimers with anionic arylsulphonate or succinate groups on intravenous pharmacokinetics and disposition. Mol Pharm. 2007; 4: 949-961.
  5. Boyd BJ, Kaminskas LM, Karellas P, Krippner G, Lessene R, Porter CJH. Cationic poly-L-lysine dendrimers: Pharmacokinetics, biodistribution and evidence for metabolism after intravenous administration to rats. Mol Pharm. 2006; 3: 614-627.